Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55.6M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
16.2M
-
Shares change
-
+16.2M
-
Total reported value, excl. options
-
$217M
-
Value change
-
+$217M
-
Number of buys
-
30
-
Price
-
$13.42
Significant Holders of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) as of Q4 2023
31 filings reported holding LXEO - Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2023.
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.2M shares
of 55.6M outstanding shares and own 29.11% of the company stock.
Largest 10 shareholders include EVENTIDE ASSET MANAGEMENT, LLC (3M shares), D1 Capital Partners L.P. (2.51M shares), JANUS HENDERSON GROUP PLC (2.33M shares), Omega Fund Management, LLC (2.16M shares), CITADEL ADVISORS LLC (2.08M shares), Novo Holdings A/S (1.31M shares), Blackstone Inc. (696K shares), Artal Group S.A. (603K shares), VANGUARD GROUP INC (416K shares), and Laurion Capital Management LP (255K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.